[Inhibition of anaphylactic reactions in atopic dogs by means of a new antiallergic drug (BM 06.001) (author's transl)].
The antiallergic action of an orally administered piperazinopropyl-adenine (BM 06.001) was demonstrated in atopic dogs. It was shown that the substance was able to inhibit both the skin reactions and the bronchial obstruction caused by ascaris antigen at approximately the same dosage.
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000707:Anaphylaxis / Q000150:complications / Q000188:drug therapy*; D000818:Animals; D001986:Bronchial Spasm / Q000517:prevention & control; D004285:Dogs; D005260:Female; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D012877:Skin Manifestations
D010879:Piperazines; D000225:Adenine
Hemmung anaphylaktischer Reaktionen bei atopischen Hunden mit einem neuen Antiallergikum (BM 06.001).